Sudarshan Pharma Industries shares rose 2.8% to ₹26.13 on Thursday, February 19, demonstrating remarkable resilience during a broader market crash. According to Samco reports, the stock opened at ₹25.50 on Thursday, compared to the previous close of ₹25.69 on BSE, before declining initially before recovering all losses. The stock touched ₹26.13 during the session and was trading 1.25% higher at ₹26 per share as of 1:50 pm. This 2% intraday recovery during a market crash tells a significant story about focused buying interest, with the gains attributed to company-specific operational developments rather than broader market sentiment.
The stock gains were triggered by Sudarshan Pharma's successful receipt of two key certifications for its manufacturing facility located in Hyderabad, Telangana. As reported by Samco, the company received a Certificate of Compliance from UK Certification & Inspection Limited for Good Manufacturing Practice (GMP) norms covering manufacturing of API intermediates and Active Pharmaceutical Ingredients. Additionally, a certificate of confirmation was obtained from Staunchly Management and System Services Private Limited for Quality Management System standards for the same manufacturing operations. The management stated that these certifications strengthen the company's commitment to global quality benchmarks and robust manufacturing standards, with certifications building credibility and validating operational systems that open doors in regulated and semi-regulated markets.
The company demonstrated robust financial growth in Q3FY26, with net sales increasing 16% year-on-year to ₹168.01 crore compared to the same quarter in the previous year. According to Samco reports, net profit for the quarter surged 51% to ₹4.36 crore over Q3FY25. For the nine months ended FY26, net sales surged 40% to ₹482.14 crore while net profit rose 67% to ₹12.58 crore compared with the corresponding period last year. On a full-year basis, the company posted net sales of ₹505 crore in FY25, marking a 9% rise over FY24, with net profit increasing 45% to ₹16 crore. These numbers demonstrate significant bottom-line growth in a competitive pharma environment, with the company's focus on API intermediates and pharmaceutical ingredients segment showing strong operational performance.
Sudarshan Pharma has expanded its international presence by establishing a wholly owned subsidiary, Sudarshan Pharma Company Poland Limited Liability, headquartered in Warsaw. As reported by Samco, following board approval in February 2025, the company invested PLN 5,000 to secure a 100% ownership stake in the entity. This initiative aims to broaden the company's customer base across European markets and strengthen its positioning as a reliable and compliant manufacturer in the API and pharmaceutical intermediates segment. International presence can diversify revenue streams, with global distribution networks playing a critical role in scaling operations for API manufacturers.
Despite recent gains, the stock has experienced volatility over longer periods, shedding 21% in the last six months and 26% in one year. According to Samco data, the small-cap stock has proven to be a significant wealth multiplier by skyrocketing 315% since its listing in March 2023. The stock hit a 52-week high of ₹53.50 on January 7, 2025, and a 52-week low of ₹18.50 on January 29, 2026. The current price remains well below its yearly high but above the recent 52-week low, with the wider volatility band reflecting the nature of small-cap pharma stocks. Sudarshan Pharma shares are listed only on the BSE, with the company's commitment to global quality benchmarks and robust manufacturing practices positioning it well for continued growth in the pharmaceutical intermediates segment.
